Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SPOP expression distinguished histological subtypes of RCC and facilitated identification of clear cell RCC as the primary tumor for metastatic lesions.
|
19164706 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we demonstrate that restoration of SPOP expression inhibited SRC-3-mediated oncogenic signaling and tumorigenesis, thus positioning SPOP as a tumor suppressor.
|
21577200 |
2011 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SPOP was the most frequently mutated gene, with mutations involving the SPOP substrate-binding cleft in 6-15% of tumors across multiple independent cohorts.
|
22610119 |
2012 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This tumor suppressor effect is abrogated by the PC-associated SPOP mutations.
|
23559371 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies reported that SPOP may be a tumor suppressor gene (TSG) and somatic mutation of SPOP was detected in prostate cancer (PCA).
|
23216165 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Altered expression and somatic mutations of SPOP have been observed in various tumor types with chromosomal aberrations, indicating a role of SPOP in maintaining genome stability, although a detailed mechanism remains unclear.
|
24451148 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In support of these results, tumor xenografts composed of prostate adenocarcinoma cells expressing mt-SPOP exhibited higher AR protein levels and grew faster than tumors composed of prostate adenocarcinoma cells expressing wt-SPOP.
|
25274033 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High SPOP expression is negatively correlated with lymph node metastasis, poor histological differentiation, and tumor malignancy according to TNM staging.
|
25204354 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results suggested that one novel oncogene (CAPRIN2) and three tumor suppressors (SPOP, OR5I1, and CDC20B) influence HB cell growth.
|
24912477 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, SPOP acts as a tumor suppressor by promoting senescence through degrading SENP7.
|
26527005 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time polymerase chain reaction analysis showed a lower level of SPOP expression in tumors carrying SPOP mutations than their matched normal prostate tissues.
|
24994784 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, SPOP expression was observed to negatively correlate with the tumor grade and intrahepatic metastasis of HCC patients.
|
26156804 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts.
|
26544944 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, decreased SPOP was associated disease progression in glioma samples, the expression level of SPOP was positively correlated with mean tumor diameter (MTD) (P=0.021) and the status of tumor grade and histological type (WHO I, II, III and IV) (P=0.032) in glioma patients.
|
25351530 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, our results help to elucidate the tumor suppressor role of SPOP in the prostate cancer setting by negatively controlling BET proteins stability.
|
29108467 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SPOP mutations were investigated from tumor DNA by Sanger sequencing.
|
28699202 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRNA downregulation, suggesting an important tumour suppressor function.
|
28414305 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, our study not only underlines an oncogenic role of EglN2 in prostate cancer, but also highlights SPOP as a tumor suppressor to down-regulate EglN2 in prostate cancer.
|
28089830 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Detected alterations included AR amplifications in 22 (64.7%) samples, SPOP mutations in three (8.8%) samples, and inactivating alterations in tumor suppressors TP53 , PTEN , RB1 , APC , CDKN1B , BRCA2 , and PIK3R1 .
|
29206995 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers.
|
28810879 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Speckle-type POZ protein (SPOP) is a member of the MATH-BTB protein family and is a type of joint molecule for Cullin-3.SPOP inhibits tumor growth.
|
28928843 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our data identify the tumor suppressor SPOP as an upstream negative regulator for HDAC6 stability, and SPOP loss-of-function mutations might lead to elevated levels of the HDAC6 oncoprotein to facilitate tumorigenesis and metastasis in various human cancers.
|
28599312 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, SPOP acts as a tumor suppressor via destabilizing downstream oncoproteins in many malignancies, especially in prostate cancer.
|
29128526 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments.
|
30244836 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To identify molecular mediators of the tumor suppressive function of SPOP, we performed a yeast two-hybrid screen in a HeLa cDNA library using the full-length SPOP as bait.
|
29996942 |
2018 |